查看完整行情页>>

|

货币单位:美元(USD)

BioPlus Acquisition Corp. (bios)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
Jonathan M. N. Rigby Founder of Zogenix, Inc., Jonathan M. N. Rigby is a British businessperson who has been at the head of 6 different companies and holds the position of Chairman & Chief Business Officer at BioPlus Acquisition Corp. and Group Chief Executive Officer & Director at Revolo Biotherapeutics Ltd. He is also on the board of Oncolytics Biotech, Inc., Thermalin, Inc. and ImmunoMolecular Therapeutics, Inc. and Chairman of Association of Needle-Free Injection Manufacturers. In the past Mr. Rigby held the position of Chairman at CollPlant Biotechnologies Ltd., President, Chief Executive Officer & Director at SteadyMed Therapeutics, Inc., Principal at Merck & Co., Inc., Vice President-Business Development at Aradigm Corp., President, Chief Executive Officer & Director at SteadyMed Ltd., Vice President-Business Development of Zogenix, Inc. and Head-Business Development & Sales at Respironics Ltd. Jonathan M. N. Rigby received an undergraduate degree from The University of Sheffield and an MBA from the University of Portsmouth.
Ross Haghighat Mr. Ross Haghighat is a Director, Chief Executive & Financial Officer at Enterprise 4.0 Technology Acquisition Corp., a Co-Chief Executive Officer & Director at Epiphany Technology Acquisition Corp., a Chairman at FRX Polymers, Inc., a Chairman, President, CEO & Treasurer at Triton Systems, Inc., a Chairman at FRX Innovations, Inc., a Chief Executive & Financial Officer, Director at BioPlus Acquisition Corp., an Executive Chairman at Avertix Medical Systems, Inc., a Managing Partner at Newburyport Partners Pty Ltd. and a Partner at Jasper Capital Partners. He is on the Board of Directors at Enterprise 4.0 Technology Acquisition Corp., Epiphany Technology Acquisition Corp., Fluence Corp. Ltd., Emefcy Ltd., SI2 Technologies, Inc., BioPlus Acquisition Corp., ACT Ltd. and Electriq Global Ltd. Mr. Haghighat was previously employed as an Independent Director by CITIC Capital Acquisition Corp., an Independent Non-Executive Director by Emefcy Group Ltd., a Chairman by iSonea Ltd., an Independent Director by Chinook Therapeutics, Inc., an Independent Director by Aduro BioTech, Inc., a Co-Founder by CoreTek, Inc., and a Senior Engineer by Foster-Miller, Inc. He also served on the board at Mavatar Technologies, Inc., Redrock Biometrics, Inc. and Sensera, Inc. He received his undergraduate degree from Rutgers State University of New Jersey, a graduate degree from Rutgers State University of New Jersey and an MBA from Boston College.
Stephen A. Sherwin Stephen A. Sherwin founded Abgenix, Inc. and Ceregene, Inc. Presently, he is Advisory partner at Third Rock Ventures LLC. Dr. Sherwin is also Professor at The University of California, San Francisco, Member of American Society of Clinical Oncology, Inc., Member of American Association for Cancer Research and Clinical Professor at the University of California and on the board of 6 other companies. In his past career Dr. Sherwin held the position of Chairman & Chief Executive Officer at Cell Genesys, Inc., Chairman for Abgenix, Inc., Chairman for Ceregene, Inc., Vice President-Clinical Research at Genentech, Inc., Director at Biogen Idec New Ventures, Inc. and Chairman-Emeritus at Biotechnology Innovation Organization. He received an undergraduate degree from Yale University and a doctorate from Harvard Medical School.
Shawn Mikael Cross Shawn Mikael Cross is on the board of Cyclo Therapeutics, Inc. and BioPlus Acquisition Corp. In his past career he held the position of Chairman & Chief Executive Officer at GT Biopharma, Inc., Chairman & Chief Executive Officer for Applied Molecular Transport, Inc., Principal at Deutsche Bank AG, Principal at Alex. Brown & Sons, Inc., Managing Director at Wells Fargo Securities LLC, Principal at Deutsche Bank Securities, Inc., Managing Director at Citizens JMP Securities LLC, Principal at Thomas Weisel Partners LLC and Principal at the University of Washington Medical Center. Mr. Cross received an undergraduate degree from the University of California, Los Angeles and an MBA from Columbia Business School.
Louis G. Lange Louis G. Lange is an entrepreneur and businessperson who founded CV Therapeutics, Inc., Rapidscan Pharma Solutions, Inc., Cardiogen Sciences, Inc. and Amygdala Neurosciences, Inc. and who has been the head of 6 different companies. Presently, Dr. Lange occupies the position of Executive Chairman of Amygdala Neurosciences, Inc. and Partner at Asset Management Ventures LLC. Louis G. Lange is also on the board of 13 other companies. Dr. Lange previously held the position of Chairman for CymaBay Therapeutics, Inc., Chairman for CardioDx, Inc., Executive VP-Cardiovascular Therapeutics at Gilead Sciences, Inc. and Chairman, CEO & Chief Scientific Officer at CV Therapeutics, Inc. (a subsidiary of Gilead Sciences, Inc.), Member-Executive Committee at Synecor LLC, Advisor at VantagePoint Management, Inc., Chairman of Rapidscan Pharma Solutions, Inc., Chief-Cardiology Division & Professor at Jewish Hospital, Chairman of Institute for Systems Biology, Faculty Member at Washington University in St. Louis, Professor at Harvard University, Principal at the University of Washington and Director at Cardiogen Sciences, Inc. He received a doctorate from Harvard Medical School, a doctorate from Harvard University and an undergraduate degree from the University of Rochester.
Glen Giovannetti Glen Giovannetti is on the board of XWPharma Ltd. and 5 other companies. In the past Mr. Giovannetti was Partner at Ernst & Young LLP. He received an undergraduate degree from Linfield College.